Jay Pepose - 07 Jun 2021 Form 4 Insider Report for Ocuphire Pharma, Inc. (IRD)

Role: Director
Issuer symbol: IRD
Report date: 07 Jun 2021
Net transaction value: $0
Form type: 4
Accepted by SEC: 09 Jun 2021, 18:21:48 UTC
Next filing: 15 Sep 2021
SEC filing: View on sec.gov
Reporting owner signature: /s/ Emily J. Johns, by Power of Attorney

Key filing fact

Jay Pepose filed Form 4 for Ocuphire Pharma, Inc. (IRD) on 09 Jun 2021.

Key facts

This page summarizes Jay Pepose's Form 4 filing for Ocuphire Pharma, Inc. (IRD).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Jun 2021, 18:21.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OCUP transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +40,000
Change %
Price: $0.000000
Shares after: 40,000
Date: 07 Jun 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,000
Exercise price: $5.74
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Will vest in a series of three successive equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's continuing service through each applicable vesting date.